Burlington, Massachusetts, U.S., October 5, 2026
Consano Bio, Inc., a clinical-stage biotechnology company developing therapeutics for painful orthopedic conditions, has announced the completion of an oversubscribed financing that raised more than $15 million to support the continued clinical development of its lead investigational therapy, C-1101, for chronic painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. The financing was subscribed by a syndicate of accredited private investors and brings the company’s total capital raised to more than $45 million since its inception. The newly secured funding is expected to support completion of the ongoing Phase 1 clinical study, further development of C-1101, and expansion of the scientific and intellectual property foundation surrounding the therapeutic.
Funding Supports Phase 1 C-1101 Clinical Trial
Consano Bio plans to use the financing to complete its randomized, double-blind Phase 1 clinical trial, designated C-1101-101 and registered as NCT07264270. The study is evaluating C-1101 in patients with chronic painful lumbosacral radiculopathy, a condition associated with irritation or damage to spinal nerve roots in the lower back that can cause pain, numbness, and weakness extending into the leg. The trial is enrolling patients in Australia and the United States, with enrollment expected to be completed in early 2027. According to the company, clinical data from the Phase 1 study are expected in the first half of 2027 and are intended to guide subsequent clinical development. The company is also using the proceeds to strengthen the scientific foundation and intellectual property portfolio surrounding C-1101 and additional pipeline assets.
C-1101 Targets Underlying Nerve Injury
C-1101 is being developed as a novel platelet-derived multi-protein biologic therapeutic designed to address the underlying biological processes associated with chronic sciatica. Rather than focusing solely on temporary pain relief, the investigational therapy is intended to modulate inflammation and stimulate cellular repair at the site of nerve injury. C-1101 contains consistent concentrations of cytokines, growth factors, and matrix proteins that are designed to support the body’s natural healing response. The therapy is administered through an epidural injection, with the goal of delivering supraphysiologic concentrations of these proteins directly to the affected area. Consano Bio describes C-1101 as a potential first-in-class disease-modifying therapy and is initially evaluating its use in chronic LSR, while the company believes the underlying approach could potentially be applicable to additional painful orthopedic conditions.
Advertisement
FDA Fast Track Designation Strengthens Development
Chronic painful LSR represents a significant subset of low back pain and can substantially affect mobility, daily functioning, and quality of life. Consano Bio notes that there are currently no FDA-approved pharmaceutical treatments specifically for chronic sciatica, leaving patients dependent on treatment approaches that may provide incomplete or temporary relief. The condition is also associated with substantial healthcare utilization and has been identified as a contributor to opioid initiation and chronic opioid use. In August 2026, the FDA granted C-1101 Fast Track designation for the treatment of LSR, providing an important regulatory milestone as the company advances the program. The latest financing gives Consano Bio resources to complete its first clinical study and evaluate C-1101 against an epidural saline injection. With Phase 1 enrollment progressing and clinical data anticipated in the first half of 2027, the company is building the clinical evidence needed to determine the next stage of development for its investigational biologic. C-1101 remains an investigational therapy and has not been approved by the FDA or any other health authority.
Source: Consano Bio press release
